Safety
Well-tolerated and a favorable safety profile1,2
XACDURO achieved primary safety endpoint in ATTACK2
Significantly lower incidence of nephrotoxicity with XACDURO versus colistin based on modified RIFLE criteria* at any post-baseline visit, the primary safety endpoint2
For patients with creatinine clearance <45 mL/min or ≥130 mL/min, please see Full Prescribing Information.
RIFLE (risk, injury, failure, loss, or end-stage renal disease) measured by creatinine level or glomerular filtration rate, but not urinary output. Nephrotoxicity defined as meeting any of the RIFLE criteria at any post-baseline visit; if patients had multiple RIFLE events, the patient was counted only once at the highest severity. No patients in this study experienced end-stage renal disease. Nephrotoxicity analysis excluded 1 patient in the colistin group with chronic hemodialysis at baseline.
XACDURO Safety Profile1,2
Selected Adverse Reactions (>5% frequency)
Slide table to view more
| Adverse Reaction | XACDURO (N=91) n (%) | Colistin (N=86) n(%) |
|---|---|---|
| Any adverse reaction | 80 (88) | 81 (94) |
| Liver test abnormalities† | 17 (19) | 18 (21) |
| Diarrhea | 15 (17) | 9 (11) |
| Anemia | 12 (13) | 12 (14) |
| Hypokalemia | 11 (12) | 9 (11) |
| Arrhythmia | 8 (9) | 8 (9) |
| Acute kidney injury† | 5 (6) | 31 (36) |
| Thrombocytopenia | 5 (6) | 3 (4) |
| Constipation | 5 (6) | 5 (6) |
Liver test abnormalities includes the following adverse reactions: liver function test abnormal, hepatic function abnormal, increased transaminases, ALT increased, and AST increased; Acute kidney injury includes the following adverse reactions: renal impairment, blood Cr increased, toxic nephropathy, renal failure and acute kidney injury.
Adverse reactions leading to discontinuation of treatment occurred in 11% (10/91) of XACDURO patients vs. 16% (14/86) of colistin patients. One patient treated with XACDURO developed anaphylactic shock which led to discontinuation of treatment.2
Want to know more?
Request to speak with a XACDURO sales representative or receive information.
Treat with Precision.
Choose pathogen-targeted coverage for HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex with XACDURO.2
References:
1. XACDURO®. Package Insert. Innoviva Specialty Therapeutics, Inc.; 2023. 2. Kaye KS, et al. Lancet Infect Dis. 2023;11:s1473‑3099(23)00184‑6. doi:10.1016/s1473‑3099(23)00184‑6